lancastotug (AK127) / Akesobio 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lancastotug (AK127) / Akesobio
NCT06530251: A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Not yet recruiting
1/2
280
RoW
AK112, Cadonilimab, AK127, AK130, Sintilimab Injection, Bevacizumab biosimilar
Akeso
Hepatocellular Carcinoma
06/26
09/28
NCT05951608: A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
216
NA
AK127 in combination with AK112
Akeso
Advanced Solid Tumors
07/25
07/26
NCT05393063: A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

Not yet recruiting
1
36
NA
AK127, Subjects will receive AK127 by intravenous administration
Akeso
Advanced Solid Tumors
06/23
06/24
NCT05021120: A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Active, not recruiting
1
66
RoW
AK127, AK104
Akesobio Australia Pty Ltd
Advanced or Metastatic Solid Tumours
10/24
05/25
NCT05868876: A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Recruiting
1
205
RoW
AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
Akeso
Advanced Malignant Tumors
11/25
02/26

Download Options